
Many group insurance plans in Canada cover Ozempic and Mounjaro, usually when they're prescribed for Type 2 diabetes. Coverage for Wegovy and Zepbound depends on each plan's drug list, and weight-loss coverage is uncommon. Public drug programs only help specific groups, and the rules vary by province. A Leger survey estimates that almost 3 million Canadian adults take a GLP-1. Generic semaglutide began appearing in Canadian pharmacies in 2026, at reported prices of about $100 a month. Here's what HR leaders and founders need to know about coverage, costs and supporting employees already on treatment.
Often, yes, when it's prescribed for Type 2 diabetes. Health Canada approved Ozempic and Mounjaro to treat Type 2 diabetes, and many private drug plans reimburse them for that use. When Ozempic is prescribed "off-label" for weight loss, some group plans refuse the claim. Coverage for Wegovy and Zepbound depends on the plan's drug list, the approved use and any authorization rules.
GLP-1s copy a hormone that helps control blood sugar and slows digestion. Several brands contain the same or similar molecules, but each one is approved for specific uses. Many insurers base their coverage on those approvals.
| Drug | Molecule | Main approved use in Canada | Group coverage |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | Often covered for Type 2 diabetes |
| Generic semaglutide (generic Ozempic) | Semaglutide | Type 2 diabetes | May be covered if the plan includes it. With generic substitution, Ozempic may be reimbursed at the generic price. |
| Mounjaro | Tirzepatide | Type 2 diabetes | Often covered for Type 2 diabetes |
| Wegovy | Semaglutide (higher dose) | Chronic weight management | Depends on the plan's drug list and the approved use |
| Sevmia (generic Wegovy) | Semaglutide (higher dose) | Chronic weight management | Depends on the plan's drug list and the approved use |
| Zepbound | Tirzepatide | Chronic weight management, and obstructive sleep apnea in adults with obesity | Depends on the plan's drug list and the approved use |
Every plan is different, so the best way to know what's covered is to check your own plan's drug list.
Public drug coverage varies by province and territory. In Ontario, Ozempic has been a Limited Use benefit on the Ontario Drug Benefit (ODB) since January 31, 2024. Eligible ODB recipients can get it covered if they have Type 2 diabetes and meet the Limited Use criteria.
The ODB program mainly covers:
Across Canada, Canada's Drug Agency (CDA-AMC) notes that most public drug plans don't fund drugs for chronic weight management.
What this means for employers: children aged 24 and under can't get OHIP+ while they're covered by a private plan. Employees who don't qualify for a public drug program may rely mainly on their group plan.
Because GLP-1s are expensive and widely used, insurers often add a check before paying. Two common approaches are prior authorization and step therapy.
The member and their doctor fill in a form that explains the diagnosis and past treatments. The insurer reviews it before approving the drug. Some large Canadian insurers use prior authorization for Ozempic. For the employee, this means paperwork, a doctor's visit and a wait before the first claim goes through.
The insurer checks whether the member has already tried a first-line drug for Type 2 diabetes, such as Metformin. Under some step therapy programs, the claim can be approved automatically once the member has met this requirement. Each insurer has its own process.
Prices have dropped a lot this year. On April 28, 2026, Canada became the first G7 country to approve a generic version of semaglutide. By late May, Canadian pharmacies were reporting prices of about $100 a month for generic semaglutide for Type 2 diabetes. Prices and stock vary by dose, pharmacy and supply. Several generic makers have been approved since then.
Novo Nordisk Canada offers a savings card that brings brand-name Ozempic close to the generic price for eligible patients, including some people with private drug plans. It isn't available in Quebec.
Other GLP-1s still cost more. Before generics arrived, list prices for brand-name GLP-1s in Canada were reported at about $200 to $400 a month, depending on the drug and the dose.
Cost is still a barrier. In a February 2026 Leger survey, about a quarter of respondents taking a GLP-1 said they paid for it entirely out of pocket.
Alan's standard plans cover GLP-1s for Type 2 diabetes like any other prescription drug, with step therapy managed through TELUS Health. Alan covers prescription drugs that have a Health Canada DIN (drug identification number), are prescribed by a licensed doctor or practitioner, and are dispensed by a pharmacist.
| Situation | Covered on Alan's standard plans? |
|---|---|
| Ozempic, generic semaglutide or Mounjaro for Type 2 diabetes | Yes, through step therapy |
| GLP-1s for weight loss | No |
| GLP-1s for Type 1 diabetes or PCOS | No |
| Wegovy, Sevmia or Zepbound | No |
GLP-1s count toward the same yearly prescription drug limit as other covered drugs.
| Alan plan | Reimbursement | Yearly drug limit |
|---|---|---|
| Bear | 80% | Up to $3,000 |
| Marmot | 100% | Up to $10,000 |
| Caribou | 80% | Up to $100,000 |
| Bison | 100% | Up to $100,000 |
In Quebec, group plans must cover at least the drugs on the public RAMQ list, and provincial rules limit how much members pay for them each year. This means Quebec residents have unlimited coverage for drugs on the RAMQ list on every Alan plan, including Bear, Marmot and custom plans.
For example, for an employee outside Quebec: generic semaglutide at about $100 a month comes to about $1,200 a year. On the Bear plan, Alan would reimburse 80%, or about $960, which leaves plenty of room under the $3,000 limit. A brand-name drug at an example price of $350 a month comes to $4,200 a year. At 80%, reimbursement would reach the $3,000 limit before the end of the year. For employees who need brand-name drugs long term, a plan with a higher limit can make a real difference.
Alan's plans use generic substitution. Now that generic semaglutide is available, Ozempic is reimbursed up to the price of the generic. Employees are usually asked to try the generic first. If they can't use it, for example because of adverse side effects, their doctor can send a full note explaining why, and Alan will review the claim for the brand-name drug. Otherwise, the employee pays the difference.
This is often what worries employees most when their company changes insurer: will their treatment stop?
With Alan, employees already taking a GLP-1 for Type 2 diabetes can send proof of past treatment in the app before their coverage starts. This can be a doctor's note, a prescription, pharmacy records or claims history from their previous insurer. Alan sends it to TELUS Health on the first day of coverage. Approval is usually quick, though timing can vary.
For a drug claim of $500 or more, it's a good idea to send a quote in the Alan app before buying. It's not required, but it helps confirm how much will be reimbursed.
Want to see the full drug coverage on each plan? Explore Alan's health insurance plans in Canada.
That's up to you. Alan's standard plans don't cover GLP-1s for weight loss. On a custom plan, employers can add weight-loss coverage or exclude GLP-1s altogether. Both choices change the price of the plan.
Here are a few questions to ask before you decide:
If you run a small team, see how Alan builds group benefits for small businesses, or check pricing to compare plans.
Looking for group benefits that are clear about what they cover? Get a quote or book a demo to see how Alan works for your team.
Covered dependants generally follow the same drug rules and yearly limits as the employee, subject to the plan's eligibility and coordination rules.
It can be. Alan covers prescription drugs that have a Health Canada DIN, are prescribed by a licensed doctor or practitioner, and are dispensed by a pharmacist. A virtual clinic prescription can qualify if it meets these criteria. The coverage rules for Type 2 diabetes still apply. Health Canada has warned about fake or unauthorized GLP-1 products sold online. Products from unauthorized sources can be unsafe and aren't eligible under Alan's plans.
No. As of November 2026, no generic version of Mounjaro or Zepbound has been approved in Canada. Generic semaglutide, the molecule in Ozempic and Wegovy, is approved for Type 2 diabetes and chronic weight management.
Some prescription drug costs that weren't reimbursed may qualify for the federal medical expense tax credit, if the CRA's requirements are met. Employees should keep their prescription and receipts, and check with the CRA or a tax professional.
Updated on 18/11/2026
Published on 16/11/2026
Updated on
18 November 2026
Share the article
Get started with Alan now
